Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Nov 23 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Famotidine Injection. The injection is used to treat stomach ulcers and related conditions. The product will be manufactured at the company's facility in Jarod, India. This approval adds to the company's portfolio, which now includes numerous approvals and filings since its inception.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases